Dren Bio, a privately held, clinical-stage biotechnology company, has entered a strategic collaboration with Sanofi for the discovery and development of a next-generation B-cell depleting therapy to treat various autoimmune diseases. The new agreement builds on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion.  DR-0201, now known as SAR448501, is currently being evaluated in two ong...